Management of Diabetic Kidney Disease with Elevated Albumin-to-Creatinine Ratio
Assessment and Diagnosis
- The American Diabetes Association recommends that a patient's albumin-to-creatinine ratio (ACR) of 319 mg/g falls into the severely increased albuminuria category (>300 mg/g), indicating significant diabetic kidney disease 1
- The patient's current medication, Trulicity (dulaglutide, GLP-1 receptor agonist), provides glycemic control with potential renoprotective effects 2
Recommended Medication Additions
- The American College of Cardiology recommends adding an SGLT2 inhibitor (such as canagliflozin, empagliflozin, or dapagliflozin) to the current regimen for patients with type 2 diabetes and albuminuria >300 mg/g 3, 2
- SGLT2 inhibitors have demonstrated significant renoprotective effects independent of glycemic control in patients with type 2 diabetes and albuminuria 3
- The CREDENCE trial showed that canagliflozin reduced the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and albuminuria >300 mg/g 2
Monitoring and Management
- The American Diabetes Association recommends monitoring glycemic control regularly and assessing for side effects of SGLT2 inhibitors, particularly genital mycotic infections and volume depletion 3, 2
- Ensure blood pressure is optimally controlled to <130/80 mmHg, as recommended by the American Heart Association 3
- Optimize glycemic control with target HbA1c individualized based on patient characteristics, as recommended by the American Diabetes Association 3
Rationale for Adding SGLT2 Inhibitor
- The combination of ARB (valsartan) and SGLT2 inhibitor provides complementary mechanisms for renoprotection, with ARBs blocking the renin-angiotensin system and SGLT2 inhibitors reducing hyperfiltration through tubuloglomerular feedback mechanisms 4, 3, 2
- Multiple clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of kidney disease progression in patients with type 2 diabetes and albuminuria 3, 2
- The renoprotective effects of SGLT2 inhibitors appear to be additive to those of ARBs 2
Safety Considerations
- Monitor for hypoglycemia if the patient is also on insulin or sulfonylureas, as SGLT2 inhibitors can increase the risk, as warned by the Food and Drug Administration 2
- Do not discontinue the ARB (valsartan) when adding an SGLT2 inhibitor, as their combination provides additive renoprotection, as recommended by the American College of Cardiology 2
Management of High Urine Albumin/Creatinine Ratio with ARBs
Rationale for ARB Selection
- The American Diabetes Association and the Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommend ARBs as first-line therapy for patients with elevated urine albumin-to-creatinine ratio (≥300 mg/g creatinine) and for those with moderately elevated levels (30-299 mg/g creatinine), due to their efficacy in reducing proteinuria and slowing progression of kidney disease in this population 5, 6
Dosing and Monitoring Recommendations
- The Kidney Disease: Improving Global Outcomes (KDIGO) guideline suggests monitoring serum creatinine/eGFR and potassium levels within 7-14 days after initiation and at least annually, with a temporary increase in serum creatinine up to 30% being acceptable and not a reason to discontinue therapy 5, 6, 7
- The American Diabetes Association recommends considering stopping losartan only if kidney function continues to worsen or if refractory hyperkalemia develops, with regular monitoring of urine albumin-to-creatinine ratio to assess treatment response 5, 7
Additional Considerations
- The American Diabetes Association suggests never combining an ARB with an ACE inhibitor or direct renin inhibitor due to increased risk of adverse effects without added benefit, and considering adding a thiazide-like diuretic rather than another class of antihypertensive if blood pressure remains uncontrolled on maximum-dose losartan 7
- The American Heart Association recommends targeting blood pressure should be <130/80 mmHg for most patients with diabetes and hypertension, with continued monitoring for progression of diabetic kidney disease with annual urine albumin-to-creatinine ratio and eGFR measurements 7, 8